ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

GSK Gsk Plc

1,708.60
3.40 (0.20%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.40 0.20% 1,708.60 1,708.60 1,708.80 1,713.00 1,699.40 1,701.60 11,522,668 16:29:59
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 14.27 70.34B

Novartis Overhauls Portfolio With Deals Worth $25 Billion -- Update

22/04/2014 8:16am

Dow Jones News


Gsk (LSE:GSK)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Gsk Charts.
By Hester Plumridge 

ZURICH-- Novartis AG unveiled Tuesday a sweeping overhaul of its product portfolio, selling two units and buying another in a series of transactions worth more than $25 billion.

Basel-based Novartis said it is acquiring the oncology unit of Britain's GlaxoSmithKline PLC for around $14.5 billion. The Swiss pharmaceutical giant is also selling its vaccines unit to Glaxo for $5.25 billion. Both deals include provisions for milestone payments that could raise the total values.

Novartis and Glaxo are also planning to combine their consumer divisions, which sell medicines that don't require a prescription.

The deals fundamentally reshape Novartis, which has been conducting a review of its businesses since last year. The transactions bring it higher-margin products, such as cancer drugs, and remove the low-margin vaccine business, which depends on scale.

The overhaul refocuses the diversified company on areas in which it has scale to compete. The new structure marks a sea change from the era of former Chairman Daniel Vasella, who built Novartis into a sprawling health care conglomerate through acquisitions.

"The transactions mark a transformational moment for Novartis," Chief Executive Joe Jimenez said. The company said it expected sales, core operating income growth rates and margins to improve because of the deals.

The transactions also reshape GSK, focusing its business on respiratory, HIV, vaccines and consumer health products. Those four areas will account for roughly 70% of the British company's total sales.

GSK will take charge of the combined consumer health operations, which will be one of the world's largest over-the-counter drugs business with annual revenues of around GBP6.5 billion ($10.9 billion). Glaxo will own 63.5% of the business, which will be run by its current consumer health head, Emma Walmsley.

The deal will also widen Glaxo's lead as the world's largest provider of vaccines, strengthening its position in the meningitis vaccine market and the U.S. The new business will have more than 20 vaccines in development.

In a separate deal, Novartis also announced it is selling its animal health division to Eli Lilly & Co. for around $5.4 billion.

Novartis also said it has started a separate sales process for its flu business, which is excluded from the transaction with Glaxo.

Write to Marta Falconi at marta.falconi@wsj.com and Hester Plumridge at Hester.Plumridge@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires


1 Year Gsk Chart

1 Year Gsk Chart

1 Month Gsk Chart

1 Month Gsk Chart

Your Recent History

Delayed Upgrade Clock